Breaking Finance News

Cytosorbents Corporation (NASDAQ:CTSO) stock price target increased to $11.25, issued a research note today by B. Riley

In a report released on 10/07/2016 B. Riley raised the target price of Cytosorbents Corporation (NASDAQ:CTSO) to $11.25 stating a potential upside of 0.98%.

On Tuesday October 04, 2016, Brean Murray released a statement for Cytosorbents Corporation (NASDAQ:CTSO) bumped up the target price from $0.00 to $24.00 that suggested an upside of 2.51%.

Boasting a price of $5.68, Cytosorbents Corporation (NASDAQ:CTSO) traded 1.07% higher on the day. With the last stock price close up 18.84% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Cytosorbents Corporation has recorded a 50-day average of $5.70 and a two hundred day average of $4.79. Volume of trade was up over the average, with 112,818 shares of CTSO changing hands over the typical 81,740

Performance Chart

Cytosorbents Corporation (NASDAQ:CTSO)

With a total market value of $0, Cytosorbents Corporation has with a one year low of $3.11 and a one year high of $8.10 .

Brief Synopsis About Cytosorbents Corporation (NASDAQ:CTSO)

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *